CA2795408C - Methods for producing viloxazine salts and novel polymorphs thereof - Google Patents

Methods for producing viloxazine salts and novel polymorphs thereof Download PDF

Info

Publication number
CA2795408C
CA2795408C CA2795408A CA2795408A CA2795408C CA 2795408 C CA2795408 C CA 2795408C CA 2795408 A CA2795408 A CA 2795408A CA 2795408 A CA2795408 A CA 2795408A CA 2795408 C CA2795408 C CA 2795408C
Authority
CA
Canada
Prior art keywords
viloxazine
solvent
base
vol
minutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2795408A
Other languages
English (en)
French (fr)
Other versions
CA2795408A1 (en
Inventor
Likan Liang
Padmanabh P. Bhatt
David Dain
Jean-Philippe Taquet
Aleksandr Pechenov
Alexei Tchesnokov
Reynold Mariaux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Supernus Pharmaceuticals Inc
Original Assignee
Supernus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supernus Pharmaceuticals Inc filed Critical Supernus Pharmaceuticals Inc
Priority to CA2992219A priority Critical patent/CA2992219A1/en
Publication of CA2795408A1 publication Critical patent/CA2795408A1/en
Application granted granted Critical
Publication of CA2795408C publication Critical patent/CA2795408C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/34—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA2795408A 2010-04-12 2011-04-12 Methods for producing viloxazine salts and novel polymorphs thereof Active CA2795408C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2992219A CA2992219A1 (en) 2010-04-12 2011-04-12 Methods for producing viloxazine salts and novel polymorphs thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32315110P 2010-04-12 2010-04-12
US61/323,151 2010-04-12
PCT/US2011/032013 WO2011130194A2 (en) 2010-04-12 2011-04-12 Methods for producing viloxazine salts and novel polymorphs thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2992219A Division CA2992219A1 (en) 2010-04-12 2011-04-12 Methods for producing viloxazine salts and novel polymorphs thereof

Publications (2)

Publication Number Publication Date
CA2795408A1 CA2795408A1 (en) 2011-10-20
CA2795408C true CA2795408C (en) 2018-03-13

Family

ID=44065289

Family Applications (4)

Application Number Title Priority Date Filing Date
CA2795408A Active CA2795408C (en) 2010-04-12 2011-04-12 Methods for producing viloxazine salts and novel polymorphs thereof
CA2992219A Abandoned CA2992219A1 (en) 2010-04-12 2011-04-12 Methods for producing viloxazine salts and novel polymorphs thereof
CA3215310A Pending CA3215310A1 (en) 2010-04-12 2011-04-12 Methods for producing viloxazine salts and novel polymorphs thereof
CA3126096A Active CA3126096C (en) 2010-04-12 2011-04-12 Methods for producing viloxazine salts and novel polymorphs thereof

Family Applications After (3)

Application Number Title Priority Date Filing Date
CA2992219A Abandoned CA2992219A1 (en) 2010-04-12 2011-04-12 Methods for producing viloxazine salts and novel polymorphs thereof
CA3215310A Pending CA3215310A1 (en) 2010-04-12 2011-04-12 Methods for producing viloxazine salts and novel polymorphs thereof
CA3126096A Active CA3126096C (en) 2010-04-12 2011-04-12 Methods for producing viloxazine salts and novel polymorphs thereof

Country Status (8)

Country Link
US (7) US9403783B2 (cg-RX-API-DMAC7.html)
EP (1) EP2558437B1 (cg-RX-API-DMAC7.html)
JP (5) JP6196551B2 (cg-RX-API-DMAC7.html)
AU (1) AU2011240773C1 (cg-RX-API-DMAC7.html)
CA (4) CA2795408C (cg-RX-API-DMAC7.html)
ES (1) ES2552166T3 (cg-RX-API-DMAC7.html)
MX (5) MX2012011821A (cg-RX-API-DMAC7.html)
WO (1) WO2011130194A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2552166T3 (es) * 2010-04-12 2015-11-26 Supernus Pharmaceuticals, Inc. Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas
SG11201911859QA (en) 2017-06-16 2020-01-30 Beta Pharma Inc Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
CN108760719A (zh) * 2018-08-17 2018-11-06 北京理工大学 一种利用拉曼光谱分析cl-20的晶型纯度的方法
KR102927019B1 (ko) 2021-03-18 2026-02-13 슈퍼너스 파마슈티컬스, 인크. 치환된 몰폴린의 유도체 및 이의 용도
WO2023177845A1 (en) * 2022-03-18 2023-09-21 Supernus Pharmaceuticals, Inc. Process of making derivatives of substituted morpholines
WO2023248154A1 (en) * 2022-06-22 2023-12-28 Glenmark Life Sciences Limited Process for the preparation of viloxazine hydrochloride
EP4317141A1 (en) 2022-08-04 2024-02-07 Curia Spain S.A.U. Process and intermediates for the preparation of viloxazine and other 2-substituted morpholine derivatives
CN119707868A (zh) * 2023-09-27 2025-03-28 西安远大科创医药科技有限公司 一种盐酸维洛沙嗪产品杂质及其合成方法与应用
CN119707851B (zh) * 2023-09-27 2026-08-11 远大医药(西安)有限公司 一种盐酸维洛沙嗪产品杂质及其合成方法与应用
CN122422301A (zh) * 2023-12-18 2026-07-17 阿斯特罗森株式会社 (s)-维洛沙秦或其盐的改进制备方法
IT202400009022A1 (it) * 2024-04-19 2025-10-19 Cambrex Profarmaco Milano S R L Intermedi e processi per la preparazione di viloxazina

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1138405A (en) * 1966-12-28 1969-01-01 Ici Ltd Morpholine derivatives
US3712890A (en) * 1969-06-20 1973-01-23 Ici Ltd Process for making 2-aryloxymethyl morpholines
US3857839A (en) * 1969-06-20 1974-12-31 Ici Ltd For cyclising 1-aryloxy-3 beta-substituted ethylamino-2-propanols
ES411826A1 (es) * 1973-02-20 1976-01-01 Liade Sa Lab Procedimiento de obtencion de 1-ariloxi - 2 - propanolami- nas farmacologicamente activos.
JPS5188972A (en) 1975-01-29 1976-08-04 22*77 indeniruokishimechiru **4 chikanmoruhorinjudotainoseiho
JPS5283677A (en) 1976-01-01 1977-07-12 Yamanouchi Pharmaceut Co Ltd Derivative of 2-(7-indenyloxymethyl)-4-substituted morpholine
US4711887A (en) 1982-04-23 1987-12-08 Imperial Chemical Industries Plc Hydrazinopyridazine compounds
JPH06306025A (ja) * 1992-11-30 1994-11-01 Sankyo Co Ltd ジアリールアルカン誘導体
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
AU4949996A (en) * 1995-03-10 1996-10-02 Nycomed Salutar, Inc. Preparation of n-arylmethyl aziridine derivatives, 1,4,7,10-tetraazacyclododecane derivatives obtained therefrom and n-arylmethyl-ethanol-amine sulphonate esters asintermediates
AUPO565997A0 (en) * 1997-03-17 1997-04-10 Fujisawa Pharmaceutical Co., Ltd. Propanolamine derivatives
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
DE19919153A1 (de) * 1999-04-27 2000-11-02 Consortium Elektrochem Ind Herstellung von acrylierten flüssigkristallinen Verbindungen
FR2796069B3 (fr) * 1999-07-09 2001-08-24 Sanofi Synthelabo Nouveaux procedes de preparation de derives de 2-(2- arylmorpholin-2-yl)ethanol substitues, enantiomeriquement purs, et composes intermediaires utiles dans ces procedes
WO2001062236A2 (en) * 2000-02-24 2001-08-30 Pharmacia & Upjohn Company New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
US20030040436A1 (en) * 2000-10-23 2003-02-27 Emerson Ralph W. Use of benzyl ester compositions for controlling non-arthropod pest populations
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7326790B2 (en) * 2003-05-02 2008-02-05 Rigel Pharmaceuticals, Inc. Diphenylisoxazole compounds and hydro isomers thereof
JP4210573B2 (ja) 2003-10-10 2009-01-21 花王株式会社 置換フェノキシプロパノールアミン類
JP4198183B2 (ja) * 2004-05-27 2008-12-17 ファイザー・インク 選択的ドーパミンd3アゴニストとしてのアミノピリジン誘導体
US20060118002A1 (en) * 2004-12-03 2006-06-08 Sud-Chemie Inc. Organoclay composition containing quat mixtures
EP1924572B1 (en) * 2005-09-06 2009-12-30 SmithKline Beecham Corporation Regioselective process for preparing benzimidazole thiophenes
PE20070855A1 (es) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
CN100415709C (zh) * 2006-05-15 2008-09-03 西北大学 β-(3,4-二羟基苯基)-α-羟基丙酸冰片酯、其合成方法和用途
WO2008047388A2 (en) * 2006-10-20 2008-04-24 Ind-Swift Laboratories Limited Improved process for the preparation of ranolazine
EP2285770B1 (en) * 2008-06-02 2015-05-20 Cipla Limited Process for the synthesis of arformoterol
US20100069390A1 (en) * 2008-09-05 2010-03-18 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (ADHD)
US9296940B2 (en) * 2009-12-21 2016-03-29 Baker Hughes Incorporated Dithiazine derivatives
ES2552166T3 (es) * 2010-04-12 2015-11-26 Supernus Pharmaceuticals, Inc. Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas
TWI596088B (zh) * 2011-01-25 2017-08-21 陶氏農業科學公司 4-胺基-6-(經取代的苯基)吡啶甲酸酯及6-胺基-2-(經取代的苯基)-4-嘧啶羧酸酯之芳烷酯以及其等作為除草劑之用途
TWI610929B (zh) * 2012-11-21 2018-01-11 拉夸里亞創藥股份有限公司 多形體形式

Also Published As

Publication number Publication date
JP2016006062A (ja) 2016-01-14
JP2018076325A (ja) 2018-05-17
US20190300492A1 (en) 2019-10-03
MX357613B (es) 2018-07-17
EP2558437A2 (en) 2013-02-20
WO2011130194A3 (en) 2012-01-05
US10005743B2 (en) 2018-06-26
ES2552166T3 (es) 2015-11-26
MX355697B (es) 2018-04-27
US20160304475A1 (en) 2016-10-20
MX347218B (es) 2017-04-20
US9434703B2 (en) 2016-09-06
US20260008759A1 (en) 2026-01-08
MX357614B (es) 2018-07-17
US20220024885A1 (en) 2022-01-27
US9403783B2 (en) 2016-08-02
AU2011240773A1 (en) 2012-11-01
US10160733B2 (en) 2018-12-25
EP2558437B1 (en) 2015-08-05
JP2019194191A (ja) 2019-11-07
JP2017039754A (ja) 2017-02-23
US20110251198A1 (en) 2011-10-13
CA2992219A1 (en) 2011-10-20
MX2012011821A (es) 2012-11-30
AU2011240773B2 (en) 2015-04-02
US20150126735A1 (en) 2015-05-07
JP6663413B2 (ja) 2020-03-11
US20180265482A1 (en) 2018-09-20
WO2011130194A2 (en) 2011-10-20
CA3215310A1 (en) 2011-10-20
JP6196551B2 (ja) 2017-09-13
JP2013530129A (ja) 2013-07-25
AU2011240773C1 (en) 2015-08-27
CA2795408A1 (en) 2011-10-20
CA3126096A1 (en) 2011-10-20
CA3126096C (en) 2023-11-21

Similar Documents

Publication Publication Date Title
US20260008759A1 (en) Methods for producing viloxazine salts and novel polymorphs thereof
CN102372704A (zh) 脯氨酸衍生物的盐,其溶剂合物,及其生产方法
EP3481200A1 (en) Processes for the preparation of 4-alkoxy-3-(acyl or alkyl)oxypicolinamides
JP2004530638A (ja) 結晶性ベンラファクシン塩基、及び新規なベンラファクシン塩酸塩多型形状、ならびにその調製方法
TWI541235B (zh) 製備喹唑啉衍生物之方法
EP4063351A1 (en) Preparation method of quinoline derivative compounds
EP3717452B1 (en) Process for preparing acylated amphetamine derivatives
US20130237700A1 (en) Process for the preparation of taurolidine and its intermediates thereof
AU2024273952A1 (en) New polymorphs of (s)-6-chloro-2,3,4,9-tetrahydro-1h-carbazole-1-carboxamide in crystalline form
EP2655343A1 (en) Polymorphs of 3-chloro-4[(2r)-2
WO2007132990A1 (en) Process for the preparation of chiral glycidylphthalimide in highly optical purity
WO2023060022A1 (en) Synthesis of macrocyclic compounds
KR20050115323A (ko) 퀴나프릴 하이드로클로라이드의 제조방법
WO2018100565A1 (en) Process for the preparation of indoline compound
US20090247581A1 (en) Organic Compounds

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160329

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250404

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250404